No Association Linking Short-Term Proton Pump Inhibitor Use to Dementia: Systematic Review and Meta-analysis of Observational Studies

• Published in: The American journal of gastroenterology Vol. 115; no. 5; pp. 671 - 678
• Main Authors: Khan, Muhammad Ali, Yuan, Yuhong, Iqbal, Umair, Kamal, Sehrish, Khan, Mubeen, Khan, Zubair, Lee, Wade M., Howden, Colin W.
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer 01.05.2020; Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
• Subjects: Alzheimer's disease; Bias; Bibliographic literature; Cognition & reasoning; Cognition - drug effects; Cognition - physiology; Cognitive ability; Collaboration; Dementia; Dementia - etiology; Dementia - physiopathology; Disease Progression; Follow-Up Studies; Gastroenterology; Gastrointestinal Diseases - drug therapy; Humans; Meta-analysis; Observational studies; Observational Studies as Topic; Older people; Proton Pump Inhibitors - therapeutic use; Sensitivity analysis; Systematic review; Time Factors
• ISSN: 0002-9270; 1572-0241; 1572-0241
• DOI: 10.14309/ajg.0000000000000500

Long-term use of proton pump inhibitors (PPIs) has been associated with a wide variety of potentially serious adverse effects including a possible increased risk of dementia. Studies evaluating this association have reached divergent conclusions. We aimed to evaluate this proposed association further and to assess the quality of the evidence in its support. We searched MEDLINE, EMBASE, ISI Web of Science, and Cochrane databases for studies examining a link between PPI use and dementia, up to February 2019. Studies reporting summary results as hazard ratio (HR) or odds ratio (OR) were pooled using the DerSimonian and Laird random-effects model for meta-analyses. Methodological quality of individual observational studies was assessed using the Newcastle-Ottawa scale and the overall quality of evidence rated as per the GRADE approach. We identified and included 11 observational studies comprising 642,949 subjects; 64% were women. Most studies were short-term ranging from 5 to 10 years. There were 158,954 PPI users and 483,995 nonusers. For studies summarizing data as adjusted HR, pooled HR for all causes of dementia was 1.10 (0.88-1.37); for Alzheimer dementia only, it was 1.06 (0.72-1.55). For studies summarizing data as adjusted OR, pooled OR for all causes of dementia was 1.03 (0.84-1.25) and for Alzheimer dementia only 0.96 (0.82-1.11). Per Newcastle-Ottawa scale assessment, 10 studies were of high quality and 1 was of moderate quality. By applying GRADE methodology, quality of evidence for both outcomes was very low. We found no evidence to support the proposed association between PPI use and an increased risk of dementia. PPI use among patients who have a valid indication for it, should not be curtailed because of concerns about dementia risk.